Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone : Analysis of the Austrian head and neck cancer registry of the AGMT.
Teresa MagnesSandro M WagnerThomas MelchardtLukas WeissGabriel RinnerthalerFlorian HuemerMichael KoppSimon Peter GampenriederBeate MayrbäurlThorsten FürederDaniel LengerJohannes AndelAlexander EgleRichard GreilPublished in: Wiener klinische Wochenschrift (2021)
This study confirmed the importance of multimodal treatment concepts in patients with locally advanced SCCHN. Postoperative cetuximab might be an option in patients not eligible for high-dose cisplatin but cisplatin should remain the standard of care.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- high dose
- phase ii study
- end stage renal disease
- patients undergoing
- newly diagnosed
- ejection fraction
- healthcare
- chronic kidney disease
- palliative care
- prognostic factors
- low dose
- early stage
- clinical trial
- stem cell transplantation
- metastatic colorectal cancer
- quality improvement
- health insurance
- open label
- study protocol